Combining fixed- and weight-based dosing approaches may reduce costs without compromising efficacy. Read more
With no direct comparison to the standard of care and limited resources to review applications, researchers say they support the agency’s decision not to approve sintilimab. Read more
During the 2022 European Lung Cancer Congress, experts reviewed evidence on drugs targeting MET exon 14 skipping mutations and RET, HER2, and BRAF alterations. Read more
A presentation at the 2022 European Lung Cancer Congress convinced attendees that the current system for staging lung cancer needs refinement. Read more
The honor of giving the opening keynote address during ELCC recognizes Dr. Hirsch’s significant contributions to international research and education. Read more
5th edition of patient education book released; US FDA moves to prohibit tobacco flavoring. Read more
Even when treatment costs are covered, the majority of lung cancer patients experience increased expenses and/or reduced income following their diagnoses. Read more
A real-world look at diagnostic-therapeutic pathways explores how they may help provide optimal, innovative care without ballooning costs. Read more
In the search to understand the mechanisms of metastasis, researchers have expanded the spectrum of SCLC clinical specimens amenable for single-cell resolution analysis. Read more
Trial is the first to show improved efficacy and a manageable safety profile after cCRT in unresectable locally advanced stage III NSCLC regardless of PD-L1 status. Read more